Unadjusted and adjusted effect measures for the association between statin use and the risk of active TB
| Status of statin use | Statin usage rates for all the TB cases | Statin usage rates for all the controls | Effect estimates matched by age group, gender and year, RR (95% CI) | Confounder-adjusted effect estimates**, RR (95% CI) | DRS, adjusted RR (95% CI) |
|---|---|---|---|---|---|
| Current use | 134/8098=0.016 | 17 836/809 800=0.022 | 0.76 (0.64 to 0.90)** | 0.67 (0.56 to 0.80)*** | 0.64 (0.54 to 0.76)*** |
| Recent use | 52/8098=0.006 | 5812/809 800=0.007 | 0.87 (0.69 to 1.09) | 0.87 (0.66 to 1.15) | 0.78 (0.59 to 1.03) |
| Past use | 148/8098=0.018 | 16 996/809 800=0.021 | 0.86 (0.72 to 1.03) | 0.76 (0.64 to 0.90)** | 0.72 (0.61 to 0.85)*** |
| Chronic user | 160/8098=0.020 | 22 153/809 800=0.027 | 0.74 (0.63 to 0.87)*** | 0.66 (0.56 to 0.78)*** | 0.62 (0.53 to 0.72)*** |
The reference group in the calculation of RR is participants who did not use statins.
**p<0.01; ***p<0.001.
DRS, Disease Risk Score; RR, incidence rate ratio.